Literature DB >> 21658349

Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison.

Madhukar H Trivedi1, Tracy L Greer, Timothy S Church, Thomas J Carmody, Bruce D Grannemann, Daniel I Galper, Andrea L Dunn, Conrad P Earnest, Prabha Sunderajan, Steven S Henley, Steven N Blair.   

Abstract

OBJECTIVE: Most patients with major depressive disorder (MDD) require second-step treatments to achieve remission. The Treatment with Exercise Augmentation for Depression (TREAD) study was designed to test the efficacy of aerobic exercise as an augmentation treatment for MDD patients who had not remitted with antidepressant treatment.
METHOD: Eligible participants in this randomized controlled trial were sedentary individuals (men and women aged 18-70 years) diagnosed with DSM-IV nonpsychotic MDD who had not remitted with selective serotonin reuptake inhibitor (SSRI) treatment. Participants were recruited through physician referrals and advertisements. A total of 126 participants were randomized to augmentation treatment with either 16 kcal per kg per week (KKW) or 4 KKW of exercise expenditure for 12 weeks while SSRI treatment was held constant. Supervised sessions were conducted at The Cooper Institute, Dallas, Texas, with additional home-based sessions as needed to fulfill the weekly exercise prescription. The primary outcome was remission (as determined by a score ≤ 12 on the Inventory of Depressive Symptomatology, Clinician-Rated). The study took place between August 2003 and August 2007.
RESULTS: There were significant improvements over time for both groups combined (F₁,₁₂₁ = 39.9, P < .0001), without differential group effect (group effect: F₁,₁₃₄ = 3.2, P = .07; group-by-time effect: F₁,₁₁₉ = 3.8, P = .06). Adjusted remission rates at week 12 were 28.3% versus 15.5% for the 16-KKW and 4-KKW groups, respectively, leading to a number needed to treat (NNT) of 7.8 for 16 KKW versus 4 KKW. Men, regardless of family history of mental illness, and women without a family history of mental illness had higher remission rates by week 12 with higher-dose (women, 39.0%; men, 85.4%) than with lower-dose exercise (women, 5.6%; men, 0.1%) (women: t₉₅ = 2.1, P = .04; men: t₈₈ = 5.4, P < .0001) (NNT: women, 3.0; men, 1.2).
CONCLUSIONS: There was a trend for higher remission rates in the higher-dose exercise group (P < .06), with a clinically meaningful NNT of 7.8 in favor of the high exercise dose. Significant differences between groups were found when the moderating effects of gender and family history of mental illness were taken into account and suggest that higher-dose exercise may be better for all men and for women without a family history of mental illness. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00076258. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658349     DOI: 10.4088/JCP.10m06743

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  57 in total

1.  Rationale for Using Exercise in the Treatment of Stimulant Use Disorders.

Authors:  Tracy L Greer; Kolette M Ring; Diane Warden; Bruce D Grannemann; Timothy S Church; Eugene Somoza; Steven N Blair; Jose Szapocznik; Mark Stoutenberg; Chad Rethorst; Robrina Walker; David W Morris; Andrzej S Kosinski; Tiffany Kyle; Bess Marcus; Becca Crowell; Neal Oden; Edward Nunes; Madhukar H Trivedi
Journal:  J Glob Drug Policy Pract       Date:  2012

Review 2.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

Review 3.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

4.  Physical activity patterns among U.S. adults with and without serious psychological distress.

Authors:  Catherine A Okoro; Georjean Stoodt; James E Rohrer; Tara W Strine; Chaoyang Li; Lina S Balluz
Journal:  Public Health Rep       Date:  2014 Jan-Feb       Impact factor: 2.792

5.  IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY.

Authors:  Tracy L Greer; Joseph M Trombello; Chad D Rethorst; Thomas J Carmody; Manish K Jha; Allen Liao; Bruce D Grannemann; Heather O Chambliss; Timothy S Church; Madhukar H Trivedi
Journal:  Depress Anxiety       Date:  2016-05-10       Impact factor: 6.505

Review 6.  The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.

Authors:  Roger S McIntyre; Holly X Xiao; Kahlood Syeda; Maj Vinberg; Andre F Carvalho; Rodrigo B Mansur; Nadia Maruschak; Danielle S Cha
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

7.  Role of the dorsal medial habenula in the regulation of voluntary activity, motor function, hedonic state, and primary reinforcement.

Authors:  Yun-Wei A Hsu; Si D Wang; Shirong Wang; Glenn Morton; Hatim A Zariwala; Horacio O de la Iglesia; Eric E Turner
Journal:  J Neurosci       Date:  2014-08-20       Impact factor: 6.167

8.  Affect Following First Exercise Session as a Predictor of Treatment Response in Depression.

Authors:  Anisha M Suterwala; Chad D Rethorst; Thomas J Carmody; Tracy L Greer; Bruce D Grannemann; Manish Jha; Madhukar H Trivedi
Journal:  J Clin Psychiatry       Date:  2016-08       Impact factor: 4.384

Review 9.  Exercise training - A beneficial intervention in the treatment of alcohol use disorders?

Authors:  Mark Stoutenberg; Chad D Rethorst; Olivia Lawson; Jennifer P Read
Journal:  Drug Alcohol Depend       Date:  2015-11-22       Impact factor: 4.492

10.  Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder.

Authors:  Chad D Rethorst; Jian Tu; Thomas J Carmody; Tracy L Greer; Madhukar H Trivedi
Journal:  J Affect Disord       Date:  2016-04-23       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.